SBPH

HOPKINTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Please replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline. The corrected release reads: HOPKINTON, MA, Nov. 19, 2020 – Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) ("Spring Bank"), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stockholders held earlier today, Spring Bank's stockholders approved the issuance of shares of Spring Bank common stock to holders of share capital of F-star Therapeutics Limited ("F-star") in connection with its proposed combination with F-star (

HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stockholders held earlier today, Spring Bank’s stockholders approved the issuance of shares of Spring Bank common stock to holders of share capital of F-star Therapeutics Limited (“F-star”) in connection with its proposed combination with F-star (the “Exchange”). In connection with the Exchange, stockholders also approved a proposal to effect a reverse stock split of all outstanding shares of Spring Bank common stock at a

NEW YORK, Nov. 07, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: MVC Capital, Inc. (NYSE: MVC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Barings BDC, Inc. Under the terms of the merger agreement, MVC Capital shareholders will receive 0.94024 shares of Barings BDC and $0.39492 in cash for each share of MVC Capital stock. If you are an MVC Capital shareholder, click on this link to learn more about your legal rights and options: https://halpersadeh.com/actions/mvc-capital-inc-mvc-stock-merger-barings-bdc. WPX Energy, Inc. (NYSE: WPX) concerning

NEW YORK, Nov. 6, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] Inphi Corporation (NASDAQ: IPHI) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Inphi Corporation (NASDAQ: IPHI) in connection with the company's proposed mixed cash-and-stock merger with Marvell Technology Group Ltd. ("MRVL") (NASDAQ: MRVL).  Under the terms of the merge

HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the receipt of stockholder approval of the Exchange (as defined below) and the reverse stock split, to declare a one-time special dividend on each outstanding share of Spring Bank’s common stock, payable on a post-reverse stock split basis following the reverse stock split, in the form of contractual rights to receive, (x) one contingent value right (“STING Agonist CVR”) entitling the holder of each

HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced an upcoming trial-in-progress poster presentation for SB 11285 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020. SB 11285 is Spring Bank’s intravenously (IV)-administered STING agonist product candidate that is currently being evaluated in a Phase 1a/1b clinical trial as a monotherapy and in combination with Roche’s PD-L1 checkpoint inhibitor (Tecentriq®). This poster presentation wil

NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Montage Resources Corporation (NYSE: MR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Southwestern Energy Company. If you are a Montage shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/montage-resources-corporation-mr-stock-merger-southwestern/. MyoKardia, Inc. (NASDAQ: MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bristol-Myers Squibb Company for $

NEW YORK, Oct. 30, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) in connection with SBPH's merger with F-star Therapeutics Limited ("F-star"), pursuant to which SBPH will acquire F-star throug

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Covis Group S.à r.l. for $13.75 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/amag-pharmaceuticals-inc-stock-merger-covis/. Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its proposed merger with F-star Therapeutics, Limited. Under th

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) in connection with its merger with F-star Therapeutics Limited. The lawsuit seeks damages and/or equitable relief on behalf of Spring Bank shareholders under the federal securities laws. If you are a Spring Bank shareholder and would like to join the action, visit Spring Bank Class Action or contact Daniel Sadeh or Zachary Halper, free of charge, at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com to discuss your legal rights and options. Under the terms of the share exc

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (NASDAQ: SBPH) in connection with SBPH's July 29, 2020 merger and exchange agreement with privately-held biopharmaceutical company, F-star Therapeutics Limited ("F-star").  Under the terms of the proposed transaction, SBPH will acquire the issued capital of F-star and each ordinary share of F-star in exchange for SBPH shares. Following consummation of the proposed transaction, F-star will become a publicly-listed company, with F-star holders owning 61.2% of the combine

NEW YORK, Sept. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: On Deck Capital, Inc. (NYSE: ONDK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Enova International, Inc for $0.12 per share in cash and 0.092 shares of Enova common stock for each share of On Deck held. Visit our website to learn more about your rights and participate in an action: https://halpersadeh.com/actions/on-deck-capital-inc-ondk-stock-merger-enova-international/. Montage Resources Corporation (NYSE: MR) concerning potential violations of the federal securities laws and/or breaches of fiducia